Gelişmiş Arama

Basit öğe kaydını göster

dc.contributor.authorOktar, Tayfun
dc.contributor.authorKocak, Taner
dc.contributor.authorOner-Iyidogan, Yildiz
dc.contributor.authorErdem, Selcuk
dc.contributor.authorSeyithanoglu, Muhammed
dc.contributor.authorZiylan, Orhan
dc.contributor.authorKocak, Hikmet
dc.date.accessioned2019-08-13T12:10:23Z
dc.date.accessioned2019-08-13T16:03:00Z
dc.date.available2019-08-13T12:10:23Z
dc.date.available2019-08-13T16:03:00Z
dc.date.issued2013
dc.identifier.issn1477-5131
dc.identifier.issn1873-4898
dc.identifier.urihttps://dx.doi.org/10.1016/j.jpurol.2012.06.003
dc.identifier.urihttp://hdl.handle.net/11446/2973
dc.descriptionWOS: 000324027200016en_US
dc.descriptionPubMed ID: 22789557en_US
dc.description.abstractObjective: This prospective study was designed to determine urinary nerve growth factor (NGF) levels in children with overactive bladder (OAB), and to evaluate whether this factor can be used as a biomarker for diagnosis and monitoring treatment outcome. Patients and methods: Urinary NGF levels were determined in 40 children with OAB and in a control group of 20 children with no urinary symptoms. Urine samples were collected from the patients prior to and at 3 and 6 months after the beginning of treatment. The total NGF levels (pg/mL) were further normalized to the concentration of urinary creatinine (NGF/Cr level). Results: Overall, both NGF and NGF/Cr levels were significantly higher at the beginning of the study. Mean NGF levels were 30.75 +/- 8.35 and 9.75 +/- 2.11 pg/ml (p=0.023) and mean NGF/Cr levels were 0.53 +/- 0.14 and 0.16 +/- 0.04 (p = 0.022) in patients and controls, respectively. After 6 months of therapy, the NGF/Cr level was significantly reduced to almost control levels (0.16 +/- 0.02, p = 0.047). Conclusion: NGF and NGF/Cr levels were significantly higher in children with OAB than controls at initial evaluation. Furthermore, the NGF/Cr level was significantly reduced following 6 months of therapy. NGF and NGF/Cr levels show promise as reliable biomarkers for OAB diagnosis and to monitor therapy in the pediatric age group. (C) 2012 Journal of Pediatric Urology Company. Published by Elsevier Ltd. All rights reserved.en_US
dc.language.isoengen_US
dc.publisherELSEVIER SCI LTDen_US
dc.identifier.doi10.1016/j.jpurol.2012.06.003en_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectUrinary nerve growth factoren_US
dc.subjectOveractive bladderen_US
dc.subjectBiomarkeren_US
dc.titleUrinary nerve growth factor in children with overactive bladder: A promising, noninvasive and objective biomarkeren_US
dc.typearticleen_US
dc.relation.journalJOURNAL OF PEDIATRIC UROLOGYen_US
dc.departmentDBÜen_US
dc.identifier.issue5en_US
dc.identifier.volume9en_US
dc.identifier.startpage617en_US
dc.identifier.endpage621en_US
dc.contributor.authorID0000-0003-1720-9102en_US
dc.contributor.authorID0000-0002-3514-1394en_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.department-temp[Oktar, Tayfun -- Kocak, Taner -- Erdem, Selcuk -- Ziylan, Orhan] Istanbul Univ, Dept Urol, Istanbul Fac Med, TR-34093 Istanbul, Turkey -- [Oner-Iyidogan, Yildiz -- Seyithanoglu, Muhammed] Istanbul Univ, Istanbul Fac Med, Dept Biochem, TR-34093 Istanbul, Turkey -- [Kocak, Hikmet] Istanbul Bilim Univ, Dept Biochem, Fac Med, Istanbul, Turkeyen_US


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster